Plasticell

Plasticell is a private biotechnology company pioneering a high-throughput combinatorial screening platform, CombiCult®, to rapidly develop optimized cell culture protocols for regenerative medicine. Its therapeutic pipeline is centered on advanced cell and gene therapies, including iPSC-derived allogeneic cancer immunotherapies, hematopoietic stem cell expansion, and treatments for thrombocytopenia and anemia. The company operates through a collaborative business model, partnering with academic and industry leaders like Imperial College London and the Cell and Gene Therapy Catapult to advance its programs and manufacturing capabilities.

CombiCult® - A combinatorial high-throughput screening platform that tests thousands of cell culture variable combinations simultaneously to rapidly discover optimized protocols for stem cell expansion, differentiation, and gene transduction. Supported by Ariadne® bioinformatics software.

Plasticell competes with other cell therapy platform companies (e.g., using CRISPR, other screening methods) and direct therapeutic developers in allogeneic CAR-T/iPSC-derived cells (e.g., Fate Therapeutics, Century Therapeutics) and hematopoietic stem cell expansion (e.g., Gamida Cell). Its differentiation lies in the high-throughput, combinatorial nature of the CombiCult® platform for process optimization.